Gilead Sciences, Inc. (GILD) Earnings Call Transcripts
Gilead Sciences, Inc.'s Latest Earnings Call - September 10, 2026
In the September 10, 2026 earnings call, Gilead Sciences, Inc. (GILD:US) highlighted strong growth in its HIV business, particularly with the EZ2GO launch, which is tracking to exceed $1 billion in sales for the year. The company reported robust metrics, including a 70% persistence rate for the new HIV prevention treatment and a $4 billion run rate for its HIV prevention business. Management maintained a positive outlook, signaling continued growth in both the HIV treatment and prevention markets despite anticipated impacts from government price negotiations set for 2028.
Reported metrics
| Metric | Value |
|---|---|
| HIV Prevention Sales Guidance | $1B (beat) |
| HIV Prevention Business Run Rate | $4B (positive) |
| Biktarvy Market Share | 52% (positive) |
| Persistence Rate for EZ2GO | 70% (positive) |
| R&D Spending as Percentage of Revenue | 20% (neutral) |
| Expected Impact from Price Negotiations | Manageable (neutral) |
Guidance from management
Management maintained a positive outlook for the HIV treatment and prevention markets, expecting continued growth despite upcoming pricing negotiations. They reiterated confidence in managing potential impacts from government price negotiations set for 2028.
What management said
I mean, again, I can't say specifically because we're in the middle of it, but I've always said we expect that it will be manageable and more to come later this year. We can -- as we have the price, then we can talk more specifically about what it means. But in the -- when you look at where we are today, our expectation is we can absorb that, we can manage it and the business can grow through it.
What analysts pressed on
Analysts expressed concerns regarding the potential impact of government pricing negotiations on future revenue and the competitive landscape in the cell therapy market, particularly with the rise of bispecific therapies. There were questions about how Gilead plans to maintain its market position amidst these challenges.
Main topics on the call
- HIV Business Growth — Gilead's HIV business is experiencing significant growth, with the EZ2GO launch exceeding expectations. Management stated, "Every single metric of the launch is either tracking to or exceeding our expectations," and high...
- New Product Launches — The company is poised to launch a weekly oral version of lenacapavir next year, which management believes will significantly expand market access. This is part of a strategy to move patients from daily oral medications t...
- Biktarvy Market Share — Biktarvy has captured over 52% of the HIV treatment market, with over 70% of new patient initiations starting on this medication. Management noted, "Biktarvy can continue to grow," indicating confidence in its market pos...
- Regulatory Negotiations — Management is currently negotiating with the U.S. government regarding drug pricing, with expectations that the impact will be manageable. CFO Andrew Dickinson stated, "We think the impact should be manageable," suggesti...
Read the full Gilead Sciences, Inc. transcript (September 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 116 calls on record spanning January 13, 2020 to September 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 116 Gilead Sciences, Inc. earnings call transcripts on record, spanning January 13, 2020 to September 10, 2026. Based on this history, Gilead Sciences, Inc. reports quarterly. The most recent call on file is dated September 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- GILD
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 116
- First call
- January 13, 2020
- Most recent
- September 10, 2026
- Reporting cadence
- quarterly